All In Biotech

Drug Trial Radar · NCT01610336

A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment

A Phase IB/II, Open Label, Multicenter Study of INC280 Administered Orally in Combination With Gefitinib in Adult Patients With EGFR Mutated, c-MET-amplified Non-small Cell Lung Cancer Who Have Progressed After EGFR Inhibitor Treatment

Last checked: Nov 19, 2026Latest source record: Apr 8, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

161

Actual

Start

Apr 5, 2012

Primary completion

Jun 10, 2016

Study completion May 27, 2020

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jun 4, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study assessed the safety and efficacy of escalating doses INC280 when added to gefitinib in patients with lung cancer that were known to have dysregulation of the c-MET pathway and who had failed after benefiting on a prior treatment with either gefitinib or erlotinib.

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • INC280Drug

    During Phase Ib, INC280 was taken at escalating doses. During Phase II part, INC280 was taken at recommended Phase II dose.

  • GefitinibDrug

    Gefitinib 250 mg taken once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ib: Frequency of Dose Limiting Toxicities (DLTs)Time frame: Up to 215 weeks
  2. Phase II : Overall Response Rate (ORR)Time frame: Until disease progression, up to 60.8 weeks

Locations

31 sites in 14 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Auckland, Australia

  • Novartis Investigative Site

    Woolloongabba, Queensland, Australia

  • Novartis Investigative Site

    East Bentleigh, Victoria, Australia

  • Novartis Investigative Site

    Leuven, Belgium

  • Novartis Investigative Site

    Beijing, China

  • Novartis Investigative Site

    Guangzhou, China

  • Novartis Investigative Site

    Guangzhou, Guangdong, China

  • Novartis Investigative Site

    Shanghai, Shanghai Municipality, China

  • Novartis Investigative Site

    Strasbourg, France

  • Novartis Investigative Site

    Toulouse, France

  • Novartis Investigative Site

    Frankfurt, Germany

  • Novartis Investigative Site

    Freiburg im Breisgau, Germany

  • Novartis Investigative Site

    Ramat Gan, Israel

  • Novartis Investigative Site

    Milan, MI, Italy

  • Novartis Investigative Site

    Milan, MI, Italy

  • Novartis Investigative Site

    Modena, MO, Italy

  • Novartis Investigative Site

    Koto Ku, Tokyo, Japan

  • Novartis Investigative Site

    Amsterdam, Netherlands

  • Novartis Investigative Site

    Rotterdam, Netherlands

  • Novartis Investigative Site

    Maastricht, AZ, Netherlands

  • Novartis Investigative Site

    Singapore, Singapore

  • Novartis Investigative Site

    Seoul, South Korea

  • Novartis Investigative Site

    Seoul, South Korea

  • Novartis Investigative Site

    Gyeonggi-do, Korea, South Korea

  • Novartis Investigative Site

    Seoul, Korea, South Korea

  • Novartis Investigative Site

    Seoul, Seocho Gu, South Korea

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    Barcelona, Catalonia, Spain

  • Novartis Investigative Site

    Tainan, Taiwan

  • Novartis Investigative Site

    Taipei, Taiwan

  • Novartis Investigative Site

    Bangkok, Thailand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.